Stockscreener 앱 받기
13.00
0.23%
0.06
전일 마감가:
$13.06
열려 있는:
$13.08
하루 거래량:
16,346
Relative Volume:
0.02
시가총액:
$223.23M
수익:
$10.73M
순이익/손실:
$-455.74M
주가수익비율:
-5.4737
EPS:
-2.375
순현금흐름:
$-502.70M
1주 성능:
+2.91%
1개월 성능:
+1.47%
6개월 성능:
-81.71%
1년 성능:
-56.87%
1일 변동 폭
$12.95
$13.12
1주일 범위
$12.61
$13.29
52주 변동 폭
$11.95
$73.06
어비디티 바이오사이언스 Stock (RNA) Company Profile
명칭
Atrium Therapeutics Inc
전화
858-401-7900
주소
3020 CALLAN ROAD, SAN DIEGO, CA
Compare RNA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNA
Atrium Therapeutics Inc
|
13.05 | 223.40M | 10.73M | -455.74M | -502.70M | -2.375 |
VRTX
Vertex Pharmaceuticals Inc
|
444.45 | 110.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.70 | 66.53B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
830.77 | 50.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.69 | 39.45B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.29 | 32.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
어비디티 바이오사이언스 Stock (RNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 개시 | Wells Fargo | Overweight |
| 2025-09-17 | 개시 | Roth Capital | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Bernstein | Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-06-11 | 개시 | Raymond James | Strong Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-20 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-09-24 | 개시 | Goldman | Buy |
| 2024-08-28 | 개시 | Barclays | Overweight |
| 2024-05-03 | 개시 | BofA Securities | Buy |
| 2024-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-05-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-31 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Strong Buy |
| 2021-09-07 | 개시 | Evercore ISI | Outperform |
| 2021-06-17 | 개시 | Needham | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | Cowen | Outperform |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | SVB Leerink | Outperform |
| 2020-07-07 | 개시 | Wells Fargo | Overweight |
모두보기
어비디티 바이오사이언스 주식(RNA)의 최신 뉴스
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring a 90.99% Potential Upside in RNA Therapeutics - DirectorsTalk Interviews
Atrium Therapeutics Inc. (RNA) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Investor Sentiment - Newser
RNA Price Today: Atrium Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Atrium Therapeutics (RNA) Stages a Recovery: Testing Key Resistance at $13.69Crowd Stock Picks - Newser
RNA Initiated Coverage by Leerink Partners -- Rating Set to Outp - GuruFocus
RA Capital (RNA) healthcare fund discloses 864,102 shares, 5.6% stake - Stock Titan
Leerink initiates Atrium Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
Leerink Partners Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - Moomoo
Leerink Partners Initiates Coverage on Atrium Therapeutics With Outperform Rating, $25 PT - Moomoo
Atrium Therapeutics 1Q Loss/Shr 97c >RNA - Moomoo
Atrium Therapeutics Reports First Quarter 2026 Financial Results - Investing News Network
Atrium Therapeutics 1Q Rev $19.6M >RNA - Moomoo
Atrium Therapeutics Believes Cash Resources Sufficient to Fund Planned Ops Through Key Clinical Proof-Of-Concept Milestones >RNA - Moomoo
Atrium Therapeutics (RNA) Q1 2026: milestone revenue, higher R&D and $267.8M cash - Stock Titan
Atrium Therapeutics Reports Q1 2026 Financial Results and Corporate Progress - Intellectia AI
Atrium Therapeutics reports Q1 2026: $19.6M collaboration revenue, $267.8M cash - TradingView
Atrium Therapeutics, Inc. 1Q 2026: Revenue $19.6M, EPS $(0.97) — 10-Q Summary - TradingView
Atrium Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Atrium Therapeutics Q1 collaboration revenue surges after spin-off - TradingView
Atrium Therapeutics (Nasdaq: RNA) Q1 2026 results show higher revenue and loss - Stock Titan
Fierce Biotech Fundraising Tracker '26: Create corrals $122M; Isomorphic's $2B series B - Fierce Biotech
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring the 91% Potential Upside in RNA Therapeutics - DirectorsTalk Interviews
RNA (Atrium Therapeutics) revenue surges 70.8% in Q1, but shares slip as losses persist.Investment Community Signals - newser.com
How Atrium Therapeutics (RNA) performance compares to expectations (Underperforming) 2026-05-08Earnings Miss Risk - Newser
What Atrium Therapeutics (RNA) is doing to earn customer loyalty (Nudges Up) 2026-05-06Index Investing - newser.com
Atrium Therapeutics, Inc. (RNA) Stock Analysis: Exploring an 86% Potential Upside in RNA Therapeutics - DirectorsTalk Interviews
RNA 260618 33.00P (RNA260618P33000) Stock Options Chain | Quotes & News - Moomoo
Atrium Therapeutics (RNA) price target decreased by 65.57% to 25.50 - MSN
BlackRock (NASDAQ: RNA) reports 5.2% stake — 892,387 shares - Stock Titan
Atrium Therapeutics, Inc. (RNA) - DirectorsTalk Interviews
Milestone in Atrium and BMS cardiovascular collaboration - BioWorld News
BMY Secures $15M Milestone Payment to Atrium Therapeutics - GuruFocus
Atrium Therapeutics earns $15M from Bristol Myers Squibb By Investing.com - Investing.com South Africa
Atrium Therapeutics earns $15M from Bristol Myers Squibb - Investing.com
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - PR Newswire
RNA SEC FilingsAtrium Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RNA (Atrium Therapeutics Inc.) posts 70.8 percent year over year Q1 2026 revenue growth, shares rise 3.71 percent. - Xã Thanh Hà
Atrium Therapeutics grants RSUs and options to executive | RNA Insider Trading - Stock Titan
[Form 4] Atrium Therapeutics, Inc. Insider Trading Activity - Stock Titan
Atrium Therapeutics (RNA) CFO awarded 30,000 RSUs and 60,000 stock options - Stock Titan
Atrium Therapeutics (RNA) director Gallagher granted RSUs and 205,000-share option - Stock Titan
Atrium Therapeutics (RNA) CSO awarded 30,000 RSUs and 60,000 options - Stock Titan
Atrium Therapeutics (RNA) CSO granted RSUs and 60,000 stock options in Form 4 - Stock Titan
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month - Sahm
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - ChartMill
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Omdia: India’s smartphone shipments fell 5% in 1Q26 amid channel caution and pricing pressures - Weekly Voice
Atrium offers stock awards to 7 new hires under Nasdaq rule - Stock Titan
Form S-8Securities to be offered to employees in employee benefit plans - ADVFN
어비디티 바이오사이언스 (RNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
어비디티 바이오사이언스 주식 (RNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Boyce Sarah | President and CEO |
Jan 21 '26 |
Sale |
72.45 |
14,387 |
1,042,338 |
269,007 |
| Flanagan W. Michael | Chief Scientific Officer |
Jan 21 '26 |
Sale |
72.45 |
6,534 |
473,388 |
85,093 |
| MacLean Michael F | Chief Financial Officer |
Jan 21 '26 |
Sale |
72.45 |
4,542 |
329,068 |
59,290 |
| LEVIN ARTHUR A | Director |
Jan 21 '26 |
Sale |
72.45 |
1,758 |
127,367 |
16,562 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 21 '26 |
Sale |
72.45 |
2,929 |
212,206 |
113,938 |
| Boyce Sarah | President and CEO |
Jan 07 '26 |
Sale |
72.23 |
8,576 |
619,444 |
283,394 |
| Calderaro Charles III | Chief Technical Officer |
Jan 07 '26 |
Sale |
72.23 |
3,727 |
269,201 |
49,797 |
| McCarthy Teresa | Chief Human Resources Officer |
Jan 07 '26 |
Sale |
72.23 |
1,965 |
141,932 |
116,867 |
| Moriarty John B | Chief Legal Officer |
Jan 07 '26 |
Sale |
72.23 |
2,374 |
171,474 |
74,557 |
| MacLean Michael F | Chief Financial Officer |
Jan 07 '26 |
Sale |
72.23 |
1,974 |
142,582 |
63,832 |
0.67%
1.91%
자본화:
|
볼륨(24시간):